Oral Hypoglycemic Agent–Induced Hypoglycemia: Dextrose Management
Direct Recommendation
For OHA-induced hypoglycemia in unconscious or unable-to-swallow patients, administer D10W (10% dextrose) intravenously in 5–10 g aliquots (50–100 mL) every 1–2 minutes until symptoms resolve, then start a continuous D10W infusion at 50–100 mL/hour (5–10 g/hour) with close monitoring. 1, 2
Initial Bolus Treatment
Dosing Strategy
Give D10W in titrated 5–10 g aliquots (50–100 mL of 10% dextrose) every 1–2 minutes rather than a single large bolus, targeting a post-treatment glucose of 100–180 mg/dL. 1, 3
Calculate the initial dose using: (100 – current glucose mg/dL) × 0.2 g = total grams needed. This formula-based approach minimizes overcorrection while achieving target glucose in ~98% of patients within 30 minutes. 1, 3
Avoid D50W (50% dextrose) as first-line therapy because it causes significantly higher post-treatment glucose levels (9.4 mmol/L vs 6.2 mmol/L with D10W) and requires larger total doses (median 25 g vs 10 g). 4
Why D10W Over D50W?
D10W results in lower post-treatment hyperglycemia (6.2 mmol/L vs 8.5 mmol/L), fewer adverse events (0/1057 vs 13/310), and better symptom resolution (95.9% vs 88.8%) compared to D50W. 5, 4
Although D10W may take 3–4 minutes longer to achieve symptom resolution, it avoids the dangerous overcorrection and rebound hyperglycemia associated with concentrated dextrose boluses. 5, 6
Rapid or repeated D50W boluses have been linked to cardiac arrest and hyperkalemia. 1, 3
Continuous Infusion Protocol
When to Start Continuous Infusion
OHA-induced hypoglycemia requires prolonged dextrose infusion because sulfonylureas and other oral agents have long half-lives that outlast the effect of bolus dextrose. 1, 2
Standard Infusion Rate
Begin D10W at 50–100 mL/hour (5–10 g/hour) immediately after initial bolus treatment to prevent recurrent hypoglycemia. 1, 2
For severe cases or insulin overdose, the infusion rate can be increased to approximately 4.2 mL/kg/hour (≈7 mg/kg/min or 100 mL/kg per 24 hours), titrated to maintain glucose between 100–180 mg/dL. 1
Do not use D5W (5% dextrose) as it provides insufficient glucose delivery (only 2.5 g/hour at 50 mL/hour) for patients with ongoing insulin or OHA effect. 1, 2
Tapering and Discontinuation
Never abruptly stop the dextrose infusion in OHA-induced hypoglycemia; reduce the rate by 50% over the final 30 minutes before cessation to avoid rebound hypoglycemia. 1
Continue the infusion for at least 12–24 hours in sulfonylurea-induced hypoglycemia due to the prolonged drug effect. 1, 2
Monitoring Requirements
Immediate Monitoring
Recheck blood glucose 15 minutes after the initial bolus; additional doses are frequently needed (19.5% of D10W-treated patients require a second dose). 1, 3, 5
Repeat glucose measurement at 60 minutes because the dextrose effect may be transient, especially with long-acting OHAs. 1, 3
During Continuous Infusion
Monitor glucose every 1–2 hours during the continuous infusion and adjust the rate to maintain glucose between 100–180 mg/dL. 1, 2
Check serum potassium and sodium initially every 30–60 minutes when starting a continuous infusion, as dextrose administration can shift electrolytes intracellularly. 1
Critical Safety Considerations
Avoid Overcorrection
Target glucose of 100–180 mg/dL, not aggressive normalization, as hyperglycemia post-treatment worsens outcomes and complicates subsequent glucose management. 1, 3
The titrated D10W approach achieves this target in 98% of patients while minimizing dangerous overcorrection. 1
Special Pitfall in OHA-Induced Hypoglycemia
OHA-induced hypoglycemia is particularly dangerous because sulfonylureas and meglitinides continue stimulating insulin release for hours to days, requiring prolonged dextrose infusion beyond what is typical for insulin-induced hypoglycemia. 1, 2
Never discharge a patient with OHA-induced hypoglycemia after a single bolus correction; they require hospital admission with continuous dextrose infusion and monitoring. 1, 2
Practical Algorithm
Confirm hypoglycemia (glucose <3.3 mmol/L or 60 mg/dL) in unconscious or symptomatic patient. 7
Administer D10W 5–10 g (50–100 mL) IV over 1–2 minutes. 1
Start continuous D10W infusion at 50–100 mL/hour immediately after initial correction. 1, 2
Monitor glucose every 1–2 hours and adjust infusion rate to maintain 100–180 mg/dL. 1, 2
Continue infusion for ≥12–24 hours in OHA-induced cases. 1, 2
Taper by 50% over 30 minutes before discontinuation. 1